GlassScriptPhysician profile
Raj P Vallabhaneni
NPI 1124025804
$6,633.16
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $519 · 2021: $1,104 · 2022: $1,089 · 2023: $1,355 · 2024: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,287.78 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $920.41 | 2019-2024 | Farxiga, Wainua, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $635.76 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $542.55 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.67 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $503.73 | 2021-2024 | Verquvo |
| Abbott Laboratories | $303.95 | 2019-2024 | Absolute Pro, Jeti, Perclose Proglide |
| Janssen Pharmaceuticals, INC | $259.40 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.14 | 2020-2024 | Lifevest |
| Medtronic, INC. | $241.18 | 2023-2024 | Octopus, Onyx Frontier |
| Abiomed | $204.30 | 2019-2023 | Impella |
| Pfizer INC. | $179.78 | 2019-2024 | |
| Penumbra, INC. | $173.00 | 2019 | |
| Amarin Pharma, INC. | $116.72 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $87.86 | 2023-2024 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $87.44 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $74.05 | 2022-2023 | |
| Novo Nordisk INC | $62.42 | 2022-2024 | Rybelsus, Ozempic |
| Heartflow, INC. | $35.51 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $33.67 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $29.99 | 2019 | |
| Scpharmaceuticals INC. | $17.20 | 2024 | |
| Portola Pharmaceuticals, LLC | $16.03 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $13.34 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $12.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Vallabhaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.